FOGHORN THERAPEUTICS INC (FHTX)
US3441741077 - Common Stock
FHTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. Both the profitability and financial health of FHTX have multiple concerns. FHTX is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
FHTX had negative earnings in the past year.
In the past year FHTX has reported a negative cash flow from operations.
FHTX had negative earnings in each of the past 5 years.
In the past 5 years FHTX reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -34.43%, FHTX is in the better half of the industry, outperforming 66.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.43% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-26.94%
ROA(5y)-67.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for FHTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
FHTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
FHTX has more shares outstanding than it did 1 year ago.
FHTX has more shares outstanding than it did 5 years ago.
FHTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -2.24, we must say that FHTX is in the distress zone and has some risk of bankruptcy.
FHTX has a Altman-Z score of -2.24. This is comparable to the rest of the industry: FHTX outperforms 48.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.24 |
ROIC/WACCN/A
WACC9.22%
2.3 Liquidity
FHTX has a Current Ratio of 4.11. This indicates that FHTX is financially healthy and has no problem in meeting its short term obligations.
FHTX has a Current ratio of 4.11. This is comparable to the rest of the industry: FHTX outperforms 46.42% of its industry peers.
FHTX has a Quick Ratio of 4.11. This indicates that FHTX is financially healthy and has no problem in meeting its short term obligations.
FHTX's Quick ratio of 4.11 is in line compared to the rest of the industry. FHTX outperforms 47.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.11 | ||
| Quick Ratio | 4.11 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 10.69% over the past year.
FHTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 77.73%.
The Revenue has been growing by 329.86% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)10.69%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q17.39%
Revenue 1Y (TTM)77.73%
Revenue growth 3Y329.86%
Revenue growth 5YN/A
Revenue growth Q2Q38.01%
3.2 Future
FHTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.54% yearly.
FHTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 56.68% yearly.
EPS Next Y7.09%
EPS Next 2Y19.06%
EPS Next 3Y8.48%
EPS Next 5Y24.54%
Revenue Next Year-9.94%
Revenue Next 2Y2.6%
Revenue Next 3Y6.11%
Revenue Next 5Y56.68%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
FHTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FHTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.06%
EPS Next 3Y8.48%
5. Dividend
5.1 Amount
FHTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FOGHORN THERAPEUTICS INC
NASDAQ:FHTX (5/3/2024, 7:00:00 PM)
After market: 5.99 0 (0%)5.99
-0.12 (-1.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap254.99M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.43% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.11 | ||
| Quick Ratio | 4.11 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)10.69%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y7.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)77.73%
Revenue growth 3Y329.86%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y